Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Softcat forecasts strong FY25 profit growth, expects softer gains in FY26

(Sharecast News) - IT infrastructure firm Softcat said on Thursday that it now expected to deliver "high-teens growth" in full-year gross profits and "mid-teens growth" in FY operating profits as it continued to "trade well" during the fourth quarter, supported by further conversion of larger solutions projects. Softcat also said that it had remained "highly cash generative", with FY25 cash conversion expected to be towards the top end of its 85%-95% forecasts.

Looking ahead, the FTSE 250-listed group said it was "well positioned" to deliver further growth, stating that when excluding the "significant incremental contribution" from large projects in FY25, it expects to deliver low double-digit gross profit growth and high single-digit operating profit growth in FY26.

Including the contribution from large deals in the comparative period, Softcat said this translates to reported rates of "high single-digit" gross profit growth and "low single-digit" growth in operating profit.

Softcat will report its FY25 preliminary results on 22 October.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.